…different countries. But there is already a project internally that we are pushing forward to get into the next stage, the next generation of a technology platform that would be…
…taking skin cells down the pathway towards eggs, reprogramming them to embryonic-like stem cells, and then into primordial germ cells, which are early cells that emerge as an embryo develops,…
…the development of drugs to prevent and treat metastatic liver cancer. Metastasizing cancer cells are known to change the microenvironment of liver cells in ways that promote metastasis, but the…
An international research team has found a new type of T-cell that could lead to cell immunotherapies able to treat cancers beyond the reach of current CAR T-cell therapies. Market-approved…
…cells) with cells previously exposed to antigen (memory cells). They focused on the differences in the epigenetic control of the cellular machinery and the nuclear architecture of the cells, two…
…addresses this by using UM171, a small molecule designed to expand the number of stem cells while keeping them functionally intact. The expanded product contains two components: CD34+ cells that…
…trials in three years. What we think: There is a strong need for autoimmune disease drugs that are able to restrain autoimmune cells while leaving the rest of the immune…
…astrocytes are essential to tumor progression and survival. Therefore, we investigated the underlying mechanisms: How do astrocytes transform from cells that support normal brain activity into cells that support malignant…
…lymphocytes from patients’ tumor samples. The company cultures the T cells and clones the ones that target neoantigens — proteins that are on the surface of the patients’ cancer cells….
…The researchers have developed their method in the yeast Saccharomyces cerevisiae, whose cells resemble mammalian cells. The next step is to use human cells. The researchers hope their progress will…
…Cartesian Therapeutics’ Descartes-08 is an autologous mRNA CAR-T cell therapy, meaning that it uses a patient’s own T cells that have been modified with mRNA to help them better target…
Cleara Biotech has closed a $2.5 million seed financing round that it will use for progress its compounds toward clinical development. The company that develops therapies for treating different pathologies…